# Establishment and Characterization of OS-MET-R-092: A Novel Patient-Derived Cell Culture from an Osteosarcoma Bone Metastasis

**Authors:** Veronica Giusti, Leonardo Fantoni, Monica Torsello, Giorgio Frega, Arianna Martinuzzi, Giulia Sbanchi, Caterina Dalrio, Enrico Lucarelli, Chiara Bellotti, Chiara Casotti, Elena Caddeo, Ania Naila Guerrieri, Simona Paglia, Claudia Maria Hattinger, Massimo Serra, Margherita Maioli, Marco Gambarotti, Stefania Benini, Luca Cattini, Davide Maria Donati, Toni Ibrahim, Laura Mercatali

PMC · DOI: 10.3390/ijms262110540 · 2025-10-29

## TL;DR

Researchers created a new cell line from a bone metastasis of an osteosarcoma patient to better study this rare condition and test drug resistance.

## Contribution

A novel patient-derived cell line, OS-MET-R-092, was established from a bone metastasis of an osteosarcoma patient.

## Key findings

- OS-MET-R-092 cells showed low proliferation and impaired differentiation similar to SaOS-2 cells.
- The cell line exhibited resistance to multiple chemotherapy drugs and higher expression of resistance-related genes.
- OS-MET-R-092 is a valuable model for studying osteosarcoma bone metastasis and developing 3D models.

## Abstract

Bone metastases from osteosarcoma occur in only 10% of patients, and related preclinical models are lacking. A patient diagnosed with pelvic osteosarcoma developed a metachronous scapular metastasis and was treated with multi-agent chemotherapy and surgery. Patient-derived tissue fragments (PDTFs) were obtained from leftover material after diagnosis and biobanking. PDTFs were grown on chick chorioallantoic membrane, establishing an in vivo-like predictive model. Additionally, we obtained a patient-derived cell culture, OS-MET-R-092, which has been maintained in vitro for nearly one year. OS-MET-R-092 cells were authenticated based on short tandem repeats and on their morphology when grown on commercial 3D scaffolds. Using U-2 OS and SaOS-2 as controls, we characterized growth, clonogenic potential, ability to form spheroids, migration, osteogenic differentiation, and expression of related genes. OS-MET-R-092 cells showed a low proliferation rate, impaired differentiation potential, and migratory abilities comparable to SaOS-2, while expressing higher levels of some MMPs and CD44. Functionally, OS-MET-R-092 cells demonstrated a resistant phenotype to doxorubicin, cisplatin, gemcitabine, and docetaxel, corroborated by higher expression of chemo-resistance-related genes. Collectively, OS-MET-R-092 represents a valuable tool for studying bone metastasis from osteosarcoma across various experimental settings and serves as the foundational building block for composite and translatable 3D models.

## Linked entities

- **Genes:** CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960]
- **Chemicals:** doxorubicin (PubChem CID 31703), cisplatin (PubChem CID 5460033), gemcitabine (PubChem CID 60750), docetaxel (PubChem CID 148124)
- **Diseases:** osteosarcoma (MONDO:0002623)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}
- **Diseases:** osteosarcoma (MESH:D012516), Bone metastases (MESH:D009362)
- **Chemicals:** gemcitabine (MESH:D000093542), OS-MET-R-092 (-), doxorubicin (MESH:D004317), docetaxel (MESH:D000077143), cisplatin (MESH:D002945)
- **Species:** Homo sapiens (human, species) [taxon 9606], Gallus gallus (bantam, species) [taxon 9031]
- **Cell lines:** U-2 OS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0042), SaOS-2 — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0548), OS-MET-R-092 — Homo sapiens (Human), Skin squamous cell carcinoma, Cancer cell line (CVCL_LN09)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12609462/full.md

---
Source: https://tomesphere.com/paper/PMC12609462